Wednesday, December 6, 2017

Leukemia - Table of Contents alert Volume 31 Issue 12

If you are unable to see the message below, click here to view.

Come and visit us at the ASH meeting in Atlanta, Dec 9 - 11th, booth #48

Springer Nature will be at the American Society for Hematology annual meeting in Atlanta. Pick up your complimentary copy of Leukemia, Bone Marrow Transplantation, Oncogene, Nature or Nature Reviews Clinical Oncology. We look forward to welcoming you!

Volume 31, Issue 12 (December 2017)

In this issue
Original Articles
Letters to the Editor

Also new
Sign up for e-alerts Sign up for e-alerts
Recommend to your library
Web feed
Follow on Twitter
Celebrating 30 years of Leukemia — 1987 to 2017

Thank you to the editors, board members, contributors, reviewers and readers, past and present for their invaluable contributions, and for bringing the journal to this milestone.

Watch our anniversary video showing a brief impact overview >>>

Original Articles



Dysfunction of the WT1-MEG3 signaling promotes AML leukemogenesis via p53-dependent and -independent pathways OPEN

Y Lyu, J Lou, Y Yang, J Feng, Y Hao, S Huang, L Yin, J Xu, D Huang, B Ma, D Zou, Y Wang, Y Zhang, B Zhang, P Chen, K Yu, E W-F Lam, X Wang, Q Liu, J Yan and B Jin

Leukemia 2017 31: 2543-2551; advance online publication, April 12, 2017; 10.1038/leu.2017.116

Abstract | Full Text

Impact of killer-immunoglobulin-like receptor and human leukocyte antigen genotypes on the efficacy of immunotherapy in acute myeloid leukemia OPEN

E Bernson, A Hallner, F E Sander, O Wilsson, O Werlenius, A Rydström, R Kiffin, M Brune, R Foà, J Aurelius, A Martner, K Hellstrand and F B Thorén

Leukemia 2017 31: 2552-2559; advance online publication, May 22, 2017; 10.1038/leu.2017.151

Abstract | Full Text

Mitoxantrone, etoposide and cytarabine following epigenetic priming with decitabine in adults with relapsed/refractory acute myeloid leukemia or other high-grade myeloid neoplasms: a phase 1/2 study

A B Halpern, M Othus, E M Huebner, S A Buckley, E L Pogosova-Agadjanyan, K F Orlowski, B L Scott, P S Becker, P C Hendrie, T L Chen, M-E M Percival, E H Estey, D L Stirewalt and R B Walter

Leukemia 2017 31: 2560-2567; advance online publication, May 30, 2017; 10.1038/leu.2017.165

Abstract | Full Text


JAK/STAT pathway inhibition overcomes IL7-induced glucocorticoid resistance in a subset of human T-cell acute lymphoblastic leukemias OPEN

C Delgado-Martin, L K Meyer, B J Huang, K A Shimano, M S Zinter, J V Nguyen, G A Smith, J Taunton, S S Winter, J R Roderick, M A Kelliher, T M Horton, B L Wood, D T Teachey and M L Hermiston

Leukemia 2017 31: 2568-2576; advance online publication, May 9, 2017; 10.1038/leu.2017.136

Abstract | Full Text

Abundant and equipotent founder cells establish and maintain acute lymphoblastic leukaemia OPEN

A Elder, S Bomken, I Wilson, H J Blair, S Cockell, F Ponthan, K Dormon, D Pal, O Heidenreich and J Vormoor

Leukemia 2017 31: 2577-2586; advance online publication, May 10, 2017; 10.1038/leu.2017.140

Abstract | Full Text

High efficacy and safety of low-dose CD19-directed CAR-T cell therapy in 51 refractory or relapsed B acute lymphoblastic leukemia patients

J Pan, J F Yang, B P Deng, X J Zhao, X Zhang, Y H Lin, Y N Wu, Z L Deng, Y L Zhang, S H Liu, T Wu, P H Lu, D P Lu, A H Chang and C R Tong

Leukemia 2017 31: 2587-2593; advance online publication, May 15, 2017; 10.1038/leu.2017.145

Abstract | Full Text

Age-related clinical and biological features of PTEN abnormalities in T-cell acute lymphoblastic leukaemia

M Tesio, A Trinquand, P Ballerini, G Hypolite, L Lhermitte, A Petit, N Ifrah, A Baruchel, H Dombret, E Macintyre and V Asnafi

Leukemia 2017 31: 2594-2600; advance online publication, May 25, 2017; 10.1038/leu.2017.157

Abstract | Full Text


Targeting antigen-independent proliferation in chronic lymphocytic leukemia through differential kinase inhibition

E Slinger, R Thijssen, A P Kater and E Eldering

Leukemia 2017 31: 2601-2607; advance online publication, May 2, 2017; 10.1038/leu.2017.129

Abstract | Full Text

Wnt5a induces ROR1 to associate with 14-3-3ζ for enhanced chemotaxis and proliferation of chronic lymphocytic leukemia cells OPEN

J Yu, L Chen, Y Chen, M K Hasan, E M Ghia, L Zhang, R Wu, L Z Rassenti, G F Widhopf, Z Shen, S P Briggs and T J Kipps

Leukemia 2017 31: 2608-2614; advance online publication, May 3, 2017; 10.1038/leu.2017.132

Abstract | Full Text

Wnt5a induces ROR1 to complex with HS1 to enhance migration of chronic lymphocytic leukemia cells OPEN

M K Hasan, J Yu, L Chen, Bing Cui, G F Widhopf II, L Rassenti, Z Shen, S P Briggs and T J Kipps

Leukemia 2017 31: 2615-2622; advance online publication, May 3, 2017; 10.1038/leu.2017.133

Abstract | Full Text


High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma: a prospective multicentre trial by the German Cooperative PCNSL study group

B Kasenda, G Ihorst, R Schroers, A Korfel, I Schmidt-Wolf, G Egerer, L von Baumgarten, A Röth, J Bloehdorn, R Möhle, M Binder, U Keller, M Lamprecht, M Pfreundschuh, E Valk, H Fricker, E Schorb, K Fritsch, J Finke and G Illerhaus

Leukemia 2017 31: 2623-2629; advance online publication, May 31, 2017; 10.1038/leu.2017.170

Abstract | Full Text


Efficacy and safety of carfilzomib regimens in multiple myeloma patients relapsing after autologous stem cell transplant: ASPIRE and ENDEAVOR outcomes OPEN

P Hari, M-V Mateos, R Abonour, S Knop, W Bensinger, H Ludwig, K Song, R Hajek, P Moreau, D S Siegel, S Feng, M Obreja, S K Aggarwal, K Iskander and H Goldschmidt

Leukemia 2017 31: 2630-2641; advance online publication, April 25, 2017; 10.1038/leu.2017.122

Abstract | Full Text

E-selectin ligands recognised by HECA452 induce drug resistance in myeloma, which is overcome by the E-selectin antagonist, GMI-1271 OPEN

A Natoni, T A G Smith, N Keane, C McEllistrim, C Connolly, A Jha, M Andrulis, E Ellert, M S Raab, S V Glavey, L Kirkham-McCarthy, S K Kumar, S C Locatelli-Hoops, I Oliva, W E Fogler, J L Magnani and M E O'Dwyer

Leukemia 2017 31: 2642-2651; advance online publication, April 25, 2017; 10.1038/leu.2017.123

Abstract | Full Text

A novel agent SL-401 induces anti-myeloma activity by targeting plasmacytoid dendritic cells, osteoclastogenesis and cancer stem-like cells

A Ray, D S Das, Y Song, V Macri, P Richardson, C L Brooks, D Chauhan and K C Anderson

Leukemia 2017 31: 2652-2660; advance online publication, May 8, 2017; 10.1038/leu.2017.135

Abstract | Full Text

KDM6B modulates MAPK pathway mediating multiple myeloma cell growth and survival

H Ohguchi, T Harada, M Sagawa, S Kikuchi, Y-T Tai, P G Richardson, T Hideshima and K C Anderson

Leukemia 2017 31: 2661-2669; advance online publication, May 10, 2017; 10.1038/leu.2017.141

Abstract | Full Text

HDAC3 regulates DNMT1 expression in multiple myeloma: therapeutic implications

T Harada, H Ohguchi, Y Grondin, S Kikuchi, M Sagawa, Y-T Tai, R Mazitschek, T Hideshima and K C Anderson

Leukemia 2017 31: 2670-2677; advance online publication, May 11, 2017; 10.1038/leu.2017.144

Abstract | Full Text

Leptin receptor antagonism of iNKT cell function: a novel strategy to combat multiple myeloma

M Favreau, E Menu, D Gaublomme, K Vanderkerken, S Faict, K Maes, E De Bruyne, S Govindarajan, M Drennan, S Van Calenbergh, X Leleu, L Zabeau, J Tavernier, K Venken and D Elewaut

Leukemia 2017 31: 2678-2685; advance online publication, May 11, 2017; 10.1038/leu.2017.146

Abstract | Full Text

Genetic deletion of Sost or pharmacological inhibition of sclerostin prevent multiple myeloma-induced bone disease without affecting tumor growth

J Delgado-Calle, J Anderson, M D Cregor, K W Condon, S A Kuhstoss, L I Plotkin, T Bellido and G D Roodman

Leukemia 2017 31: 2686-2694; advance online publication, May 22, 2017; 10.1038/leu.2017.152

Abstract | Full Text

Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma OPEN

P G Richardson, C C Hofmeister, N S Raje, D S Siegel, S Lonial, J Laubach, Y A Efebera, D H Vesole, A K Nooka, J Rosenblatt, D Doss, M H Zaki, A Bensmaine, J Herring, Y Li, L Watkins, M S Chen and K C Anderson

Leukemia 2017 31: 2695-2701; advance online publication, June 2, 2017; 10.1038/leu.2017.173

Abstract | Full Text


Preclinical modeling of myelodysplastic syndromes OPEN

K Rouault-Pierre, S A Mian, M Goulard, A Abarrategi, A Di Tulio, A E Smith, A Mohamedali, S Best, A-M Nloga, A G Kulasekararaj, L Ades, C Chomienne, P Fenaux, C Dosquet, G J Mufti and D Bonnet

Leukemia 2017 31: 2702-2708; advance online publication, June 2, 2017; 10.1038/leu.2017.172

Abstract | Full Text


Myeloproliferative leukemia protein activation directly induces fibrocyte differentiation to cause myelofibrosis

T Maekawa, Y Osawa, T Izumi, S Nagao, K Takano, Y Okada, N Tachi, M Teramoto, T Kawamura, T Horiuchi, R Saga, S Kato, T Yamamura, J Watanabe, A Kobayashi, S Kobayashi, K Sato, M Hashimoto, S Suzu and F Kimura

Leukemia 2017 31: 2709-2716; advance online publication, April 3, 2017; 10.1038/leu.2017.112

Abstract | Full Text

Proteomic analysis of JAK2V617F-induced changes identifies potential new combinatorial therapeutic approaches OPEN

S Pearson, A J K Williamson, R Blance, T C P Somervaille, S Taylor, N Azadbakht, A D Whetton and A Pierce

Leukemia 2017 31: 2717-2725; advance online publication, May 23, 2017; 10.1038/leu.2017.143

Abstract | Full Text

A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis

F Passamonti, T Giorgino, B Mora, P Guglielmelli, E Rumi, M Maffioli, A Rambaldi, M Caramella, R Komrokji, J Gotlib, J J Kiladjian, F Cervantes, T Devos, F Palandri, V De Stefano, M Ruggeri, R T Silver, G Benevolo, F Albano, D Caramazza, M Merli, D Pietra, R Casalone, G Rotunno, T Barbui, M Cazzola and A M Vannucchi

Leukemia 2017 31: 2726-2731; advance online publication, May 31, 2017; 10.1038/leu.2017.169

Abstract | Full Text


MicroRNA-146a reduces MHC-II expression via targeting JAK/STAT signaling in dendritic cells after stem cell transplantation

N Stickel, K Hanke, D Marschner, G Prinz, M Köhler, W Melchinger, D Pfeifer, A Schmitt-Graeff, T Brummer, A Heine, P Brossart, D Wolf, N von Bubnoff, J Finke, J Duyster, J Ferrara, U Salzer and R Zeiser

Leukemia 2017 31: 2732-2741; advance online publication, May 9, 2017; 10.1038/leu.2017.137

Abstract | Full Text


Constitutively active ABL family kinases, TEL/ABL and TEL/ARG, harbor distinct leukemogenic activities in vivo

A Yokota, H Hirai, T Shoji, T Maekawa and K Okuda

Leukemia 2017 31: 2742-2751; advance online publication, April 7, 2017; 10.1038/leu.2017.114

Abstract | Full Text

Characterization of the leukemogenic potential of distal cytoplasmic CSF3R truncation and missense mutations

H Zhang, A Reister Schultz, S Luty, A Rofelty, Y Su, S Means, D Bottomly, B Wilmot, S K McWeeney and J W Tyner

Leukemia 2017 31: 2752-2760; advance online publication, April 25, 2017; 10.1038/leu.2017.126

Abstract | Full Text

Targeting HDAC3, a new partner protein of AKT in the reversal of chemoresistance in acute myeloid leukemia via DNA damage response

J Long, W Y Fang, L Chang, W H Gao, Y Shen, M Y Jia, Y X Zhang, Y Wang, H B Dou, W J Zhang, J Zhu, A B Liang, J M Li and Jiong Hu

Leukemia 2017 31: 2761-2770; advance online publication, May 2, 2017; 10.1038/leu.2017.130

Abstract | Full Text

Control of amino acid transport coordinates metabolic reprogramming in T-cell malignancy OPEN

K M Grzes, M Swamy, J L Hukelmann, E Emslie, L V Sinclair and D A Cantrell

Leukemia 2017 31: 2771-2779; advance online publication, May 26, 2017; 10.1038/leu.2017.160

Abstract | Full Text

MUC1 inhibition leads to decrease in PD-L1 levels via upregulation of miRNAs

A R Pyzer, D Stroopinsky, J Rosenblatt, E Anastasiadou, H Rajabi, A Washington, A Tagde, J-H Chu, M Coll, A L Jiao, L T Tsai, D E Tenen, L Cole, K Palmer, A Ephraim, R K Leaf, M Nahas, A Apel, M Bar-Natan, S Jain, M McMasters, L Mendez, J Arnason, B A Raby, F Slack, D Kufe and D Avigan

Leukemia 2017 31: 2780-2790; advance online publication, May 30, 2017; 10.1038/leu.2017.163

Abstract | Full Text


Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma

A Dispenzieri, C Tong, B LaPlant, M Q Lacy, K Laumann, D Dingli, Y Zhou, M J Federspiel, M A Gertz, S Hayman, F Buadi, M O'Connor, V J Lowe, K-W Peng and S J Russell

Leukemia 2017 31: 2791-2798; advance online publication, April 25, 2017; 10.1038/leu.2017.120

Abstract | Full Text

A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with less than or equal to30% blasts OPEN

G Garcia-Manero, M A Sekeres, M Egyed, M Breccia, C Graux, J D Cavenagh, H Salman, A Illes, P Fenaux, D J DeAngelo, R Stauder, K Yee, N Zhu, J-H Lee, D Valcarcel, A MacWhannell, Z Borbenyi, L Gazi, S Acharyya, S Ide, M Marker and O G Ottmann

Leukemia 2017 31: 2799-2806; advance online publication, May 26, 2017; 10.1038/leu.2017.159

Abstract | Full Text


Genotype-outcome correlations in pediatric AML: the impact of a monosomal karyotype in trial AML-BFM 2004 OPEN

M Rasche, C von Neuhoff, M Dworzak, J-P Bourquin, J Bradtke, G Göhring, G Escherich, G Fleischhack, N Graf, B Gruhn, O A Haas, T Klingebiel, B Kremens, T Lehrnbecher, A von Stackelberg, J Tchinda, Z Zemanova, C Thiede, N von Neuhoff, M Zimmermann, U Creutzig and D Reinhardt

Leukemia 2017 31: 2807-2814; advance online publication, April 25, 2017; 10.1038/leu.2017.121

Abstract | Full Text

Genomic determinants of chronic myelomonocytic leukemia

B J Patel, B Przychodzen, S Thota, T Radivoyevitch, V Visconte, T Kuzmanovic, M Clemente, C Hirsch, A Morawski, R Souaid, C Saygin, A Nazha, B Demarest, T LaFramboise, H Sakaguchi, S Kojima, H E Carraway, S Ogawa, H Makishima, M A Sekeres and J P Maciejewski

Leukemia 2017 31: 2815-2823; advance online publication, May 30, 2017; 10.1038/leu.2017.164

Abstract | Full Text


RNA editing signature during myeloid leukemia cell differentiation OPEN

C Rossetti, E Picardi, M Ye, G Camilli, A M D'Erchia, L Cucina, F Locatelli, L Fianchi, L Teofili, G Pesole, A Gallo and R Sorrentino

Leukemia 2017 31: 2824-2832; advance online publication, May 9, 2017; 10.1038/leu.2017.134

Abstract | Full Text

Letters to the Editor


Early, risk-adapted treatment with fludarabine in Binet stage A chronic lymphocytic leukemia patients: results of the CLL1 trial of the German CLL study group

M A Hoechstetter, R Busch, B Eichhorst, A Bühler, D Winkler, M J Eckart, U Vehling-Kaiser, H Schimke, U Jäger, H J Hurtz, G Hopfinger, F Hartmann, H Fuss, W Abenhardt, I Blau, W Freier, L Müller, M Goebeler, C M Wendtner, J Bahlo, K Fischer, M Bentz, B Emmerich, H Döhner, M Hallek and S Stilgenbauer

Leukemia 2017 31: 2833-2837; advance online publication, August 14, 2017; 10.1038/leu.2017.246

Full Text

The expression of P2Y14, a purinergic G-protein coupled receptor, defines functionally distinct subpopulations in placenta-derived hematopoietic stem progenitor cells

S-H Kook, H-J Sim, J-C Lee and B-C Lee

Leukemia 2017 31: 2837-2841; advance online publication, August 14, 2017; 10.1038/leu.2017.254

Full Text

The C-terminal multimerization domain is essential for leukemia development by CBFβ-SMMHC in a mouse knockin model

L Zhao, H Alkadi, E M Kwon, T Zhen, J Lichtenberg, L Alemu, J Cheng, A D Friedman and P P Liu

Leukemia 2017 31: 2841-2844; advance online publication, August 18, 2017; 10.1038/leu.2017.262

Full Text

Mechanisms of resistance to the BCR-ABL1 allosteric inhibitor asciminib

W Qiang, O Antelope, M S Zabriskie, A D Pomicter, N A Vellore, P Szankasi, D Rea, J M Cayuela, T W Kelley, M W Deininger and T O’Hare

Leukemia 2017 31: 2844-2847; advance online publication, August 18, 2017; 10.1038/leu.2017.264

Full Text

Adding molecular data to prognostic models can improve predictive power in treated patients with myelodysplastic syndromes

A Nazha, K Al-Issa, B K Hamilton, T Radivoyevitch, A T Gerds, S Mukherjee, V Adema, A Zarzour, N Abuhadra, B J Patel, C M Hirsch, A Advani, B Przychodzen, H E Carraway, J P Maciejewski and M A Sekeres

Leukemia 2017 31: 2848-2850; advance online publication, August 18, 2017; 10.1038/leu.2017.266

Full Text

Application of current prognostic models for primary myelofibrosis in the setting of post-polycythemia vera or post-essential thrombocythemia myelofibrosis OPEN

A Tefferi, L Saeed, C A Hanson, R P Ketterling, A Pardanani and N Gangat

Leukemia 2017 31: 2851-2852; advance online publication, August 18, 2017; 10.1038/leu.2017.268

Full Text



Rethinking JAK2 inhibition: towards novel strategies of more specific and versatile Janus kinase inhibition

E Leroy and S N Constantinescu

Leukemia 2017 31: 2853; 10.1038/leu.2017.158

Full Text

Gene dosage reductions of Trf1 and/or Tin2 induce telomere DNA damage and lymphoma formation in aging mice OPEN

K Hartmann, A Illing, F Leithäuser, A Baisantry, L Quintanilla-Martinez and K L Rudolph

Leukemia 2017 31: 2853; advance online publication, November 10, 2017; 10.1038/leu.2017.224

Full Text

Outcome of relapsed infant acute lymphoblastic leukemia treated on the interfant-99 protocol

E M C Driessen, P de Lorenzo, M Campbell, M Felice, A Ferster, I Hann, A Vora, L Hovi, G Escherich, C K Li, G Mann, T Leblanc, F Locatelli, A Biondi, J Rubnitz, M Schrappe, L Silverman, J Stary, R Suppiah, T Szczepanski, M Valsecchi and R Pieters

Leukemia 2017 31: 2854; 10.1038/leu.2017.279

Full Text

nature events
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.

Find the latest scientific conferences, courses, meetings and symposia on For event advertising opportunities across the Nature Publishing Group portfolio please contact
More Nature Events

Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to Leukemia. In order to do so, please purchase a subscription.

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your account at: (You will need to log in to be recognised as a registrant).

For further technical assistance, please contact our registration department.

For print subscription enquiries, please contact our subscription department.

For other enquiries, please contact our customer feedback department.

Springer Nature |One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA

Springer Nature's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne
San Diego - San Francisco - Washington - New York - Boston

Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW.

© 2017 Macmillan Publishers Limited, part of Springer Nature. All Rights Reserved.

Springer Nature

No comments: